Skip to main content

22-07-2021 | Dermatomyositis | News


IVIG receives FDA approval for dermatomyositis

Claire Barnard

medwireNews: The US FDA has approved intravenous immunoglobulin (IVIG) for the treatment of dermatomyositis in adults.

Previously approved for chronic immune thrombocytopenic purpura, IVIG may now be used for dermatomyositis at a dose of 2 g/kg divided into equal doses given over 2–5 consecutive days once every 4 weeks.

This approval is based on results from the phase 3 ProDERM trial, which demonstrated significantly higher treatment response rates among patients with active dermatomyositis who were treated with IVIG versus placebo.

The label for IVIG contains a boxed warning for thrombosis, renal dysfunction, and acute renal failure.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

JAK inhibitor safety

Data summary and expert discussion on the potential risks associated with JAK inhibitors.